Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.53 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.53 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CCL2 | P13500 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036788 | 1.00 | AADAT (0.53) | AADATKYAT1KYAT3BRD4CCL2 | |
| SCHEMBL10036777 | 1.00 | AADAT (0.53) | AADATKYAT1KYAT3BRD4CCL2 | |
| SCHEMBL3768679 | 0.86 | AADAT (0.73) | AADATKYAT1KYAT3OPRM1TIPARP | |
| SCHEMBL9886184 | 0.86 | AADAT (0.73) | AADATKYAT1KYAT3OPRM1TIPARP | |
| SCHEMBL9107683 | 0.86 | AADAT (0.73) | AADATKYAT1KYAT3OPRM1TIPARP | |
| SCHEMBL10067710 | 0.83 | AADAT (0.49) | AADATKYAT1KYAT3BRD4CCL2 | |
| SCHEMBL10036790 | 0.82 | AADAT (0.50) | AADATKYAT1KYAT3ACHE | |
| SCHEMBL10036779 | 0.82 | AADAT (0.50) | AADATKYAT1KYAT3ACHE | |
| SCHEMBL10036789 | 0.82 | AADAT (0.50) | AADATKYAT1KYAT3ACHE | |
| SCHEMBL9886179 | 0.78 | KYAT1 (0.44) | AADATKYAT1KYAT3BRD4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142729-A1 | KAT ll INHIBITORS | KAT7, KAT2A, KATNA1 | AADAT 1043/4885KYAT1 46/4885KYAT3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.